• TransCode Therapeutics' board initiated a formal strategic review to maximize the value of the company and its oncology portfolio, including TTX-MC138.
• The process will consider asset licensing or sales, development partnerships and other strategic transactions.
• Tungsten Advisors was retained as exclusive strategic financial adviser.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-119658), on October 28, 2026, and is solely responsible for the information contained therein.